Lyra Therapeutics (Nasdaq:LYRA) announced today that it closed its previously announced private placement worth $100.5 million. The company announced last week that, in the private placement, investors had the option in the private placement to purchase either shares of Lyra’s common stock at $4.22 per share or, in lieu thereof, pre-funded warrants to purchase shares […]
Funding Roundup
Diabetes tech startup Ryse Health raises $3.4M
Ryse Health, a startup providing care offerings to diabetes patients, announced today that it raised $3.4 million in seed funding. The company, which has offices in Baltimore and Arlington, Virginia, provides tech-enabled, office-based and virtual care to type 2 diabetes patients. Ryse Health’s platform includes a continuous glucose monitor (CGM) and a custom app to […]
Surf Bio raises $16M seed round for polymer-based drug delivery platform, rapid insulin
Surf Bio announced today that it raised $16 million in seed funding to advance its drug delivery offerings for treating diabetes. Palo Alto, California-based Surf Bio plans to use the funds to advance its polymer-based drug delivery platform and accelerate the development of ultra-rapid insulin for treating diabetes. According to a news release, Breakout Ventures […]
Lyra Therapeutics announces $100.5M private placement
Lyra Therapeutics (Nasdaq:LYRA) announced today that it agreed to sell securities in a private placement worth more than $100 million. The company — which develops the XTreo platform designed to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — did not list an […]
Dexcom’s board approves 4-for-1 forward stock split
Dexcom (Nasdaq:DXCM) announced today that its board of directors approved a four-for-one forward split of the company’s common stock. San Diego-based Dexcom’s stock split remains contingent upon stockholder approval of a restated certificate of incorporation. Approval of that would increase the number of authorized shares of common stock from 200 million to 800 million. According […]
DiaMonTech raises $5M for laser-based blood glucose detection system
DiaMonTech announced today that it raised $5 million to bring its total funding to more than $20 million to date. Berlin, Germany-based DiaMonTech develops a patented, mid-infrared technology platform designed to enable non-invasive blood glucose measurement using pain-free laser-based detection. The platform has ease of use comparable to the fingerprint sensor on a smartphone, according […]
Gyroscope Therapeutics to receive investment from Sanofi worth up to $60M
Gyroscope Therapeutics announced today that it received a commitment from Sanofi (NYSE:SNY) to invest up to $60 million. London-based Gyroscope will receive a $40 million investment from Sanofi initially. That $40 million represents a premium to Gyroscope’s previous Series C financing, with the remaining $20 million to be invested contingent on a future qualifying investment […]
NovaBay prices $15M private placement
NovaBay Pharmaceuticals (NYSE:NBY) announced today that it entered into a securities purchase agreement, with proceeds of approximately $15 million. Emeryville, California-based NovaBay’s agreement with certain institutional investors occurred in connection with a private placement of 15,000 shares of a newly created Series B non-voting convertible preferred stock. The Series B preferred stock comes in at […]
Better Therapeutics closes SPAC merger, debuts on Nasdaq
Better Therapeutics announced today that it completed its merger with Mountain Crest Acquisition Corp and has gone public on the Nasdaq. San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. Last month, the company confirmed its expectations for the $113 million SPAC merger to […]
Teva announces two offerings worth $7.5 billion, dips on missed Q3 projections
Teva Pharmaceuticals (NYSE:TEVA) shares took a hit today on third-quarter results that fell short of the consensus forecast. TEVA shares were down -4.7% at $8.95 per share in mid-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%. The Tel Aviv, Israel-based company posted […]
